Scope and claims for US Patent 10,449,164 (semifluorinated alkane F6H8 to solubilize meibum for keratoconjunctivitis sicca)
US Patent 10,449,164 claims a topical ophthalmic method that uses a specific liquid semifluorinated alkane, identified as F(CF2)6(CH2)8H(F6H8) and also described as “F6H8,” to solubilize and remove abnormal, obstructive meibum from obstructed meibomian gland ducts in patients with keratoconjunctivitis sicca (KCS) caused by meibomian gland dysfunction (MGD). The claims are tightly constrained to (i) route and spread pattern on the cornea or conjunctiva, (ii) absence of water and preservative (in certain claims), and (iii) administration in the absence of any therapeutically effective ophthalmic active drug substance for KCS. Dependent claims add patient features (dysfunctional ducts, lipid tear film deficiency), dosing effects (amount effective to solubilize/remove meibum), expanded anatomical application (lid margins, gland ducts, eyelashes), and optional concomitant administration with other ophthalmic active compositions (claims 5 and 9). Claim 10 and 11 narrow composition language to a formulation “consists of the F6H8.”
What is the precise claim scope of US 10,449,164 for F6H8 ophthalmic treatment? (independent method claims)
Core independent claim architecture
Your provided language reflects at least two independent-level method claims: claim 1 (method for solubilizing meibum and removing obstructive meibum in an obstructed duct patient in need) and claim 6 (method of treating KCS caused by MGD using the same F6H8 topical administration parameters). The remaining claims are dependent and mainly refine patient selection, formulation exclusions, dosing effect, and application sites.
Claim 1: solubilization/removal mechanism and patient condition constraints
Claim 1 requires all of the following in combination:
- Indication/etiology: Patient has keratoconjunctivitis sicca caused by meibomian gland dysfunction.
- Mechanistic method: Method is for solubilizing meibum and removing abnormal and obstructive meibum from obstructed meibomian gland ducts.
- Route and spread: Topically administer a liquid semifluorinated alkane to the cornea or conjunctiva so that it spreads over the corneal surface or conjunctiva.
- Material identity: The semifluorinated alkane is F(CF2)6(CH2)8H(F6H8) (and this is also stated as “F6H8” elsewhere in the claims).
- Composition exclusion: no active for KCS: Administer in the absence of any therapeutically effective amount of a pharmaceutically active drug substance useful for topical ophthalmic treatment of keratoconjunctivitis sicca.
- This is a major scope lever. The claim is not just “no other KCS drug is needed.” It requires that, at the time of administration, the dose contains no therapeutically effective amount of any pharmaceutically active drug substance useful for KCS.
Practical read: A method that applies a liquid F6H8 material on cornea/conjunctiva to spread and physically solubilize/remove abnormal meibum, where the applied material is not co-administered with therapeutically effective KCS actives.
Claim 6: treatment method tied to the same F6H8 administration constraints
Claim 6 is “method of treating KCS caused by MGD” and repeats most of the same constraints as claim 1, with added formulation exclusions:
- It requires that the semifluorinated alkane is administered in the absence of water and in the absence of a preservative (a constraint not explicitly placed in claim 1 as you provided it).
- It keeps the no therapeutically effective KCS active drug substance limitation.
- It keeps the cornea/conjunctiva topical spread requirement.
- It keeps the MGD etiology for KCS.
Dependent claims 2–5 and 7–9: how scope narrows
- Claim 2: patient has dysfunctional meibomian gland ducts.
- Claim 3: patient has lipid tear film deficiency plus KCS symptoms and MGD.
- Claim 4: semifluorinated alkane administered in absence of water and in absence of preservative (but tied as a dependent of claim 1).
- Claim 5: patient also receives concomitant or conjunction with additional eye compositions comprising pharmaceutically active ingredients (despite claim 1’s “absence of therapeutically effective amount of a pharmaceutically active drug substance useful for topical ophthalmic treatment of KCS”).
- Claim 7: dosing amount must be effective to solubilize meibum and remove abnormal and obstructive meibum.
- Claim 8: extend administration to upper/lower lid margins, meibomian gland ducts, eyelashes, or any area of eyelid anatomy.
- Claim 9: same as claim 5, but dependent from claim 6.
Claims 10–11: “consists of F6H8” composition narrowing
- Claim 10: method comprises topically administering a composition that consists of the F6H8.
- Claim 11: same limitation but dependent from claim 6.
This is a high-value claim because “consists of” is typically a closed formulation term: it limits the composition to F6H8 only (subject to legal interpretation of whether trace impurities are permitted). In practical freedom-to-operate analysis, it blocks designs that add other excipients or carrier components that are more than incidental.
Which specific elements determine infringement risk for US 10,449,164? (literal claim features checklist)
From the claims you provided, infringement risk turns on whether an accused product or method hits every required element in the asserted claim. The key discriminators:
- Active identity: must use the claimed material: F(CF2)6(CH2)8H(F6H8) / F6H8.
- Topical site: must be cornea or conjunctiva, with spread over the surface (claims 1 and 6).
- Mechanical effect goal: must be done to solubilize meibum and remove abnormal/obstructive meibum from obstructed duct(s) (claims 1 and 7).
- Patient/etiology: KCS caused by MGD, with dependent patient descriptors (dysfunctional ducts; lipid tear film deficiency).
- Formulation exclusions:
- Absence of water and absence of preservative (claims 4 and 6).
- Absence of any therapeutically effective amount of pharmaceutically active drug substance useful for topical ophthalmic treatment of KCS (claims 1 and 6).
- Application expansion: optional in dependent claims: lid margins, eyelid anatomy, eyelashes (claim 8).
- Closed composition term: “composition consists of F6H8” (claims 10–11).
What formulation restrictions are imposed by “absence of water,” “absence of preservative,” and “consists of F6H8”?
Water and preservative exclusions
Claim 6 states that F6H8 is administered in the absence of water and in the absence of a preservative. Claim 4 makes this limitation dependent on claim 1. These restrictions are commercially meaningful:
- A formulation that uses aqueous vehicles or contains preservatives risks avoiding claims 4/6, but may still implicate claim 1 if claim 1 is asserted (claim 1 as provided does not expressly require absence of water/preservative).
- However, in practice, if any formulation includes water/preservatives, the product’s functional dosing may still be argued to meet claim 1 (since claim 1 does not require absence of water/preservative), unless water/preservatives are treated as “therapeutically effective” active drugs (they usually are not, but the claim language is about active drug substances for KCS).
Closed composition “consists of”
Claims 10 and 11 require that the applied composition consists of F6H8. A carrier, co-solvent, surfactant, viscosity modifier, osmoprotectant, anti-inflammatory, antibiotic, antihistamine, lipid, or lubricant ingredient generally adds components beyond “F6H8” and increases the risk that the “consists of” limitation is not met.
Net:
- The broad method claims (1/6) tolerate other inactive materials unless those other components are framed as a therapeutically effective amount of a pharmaceutically active drug substance useful for KCS treatment (claims 1/6).
- The “consists of F6H8” dependent claims are strict and favor a product that is essentially neat F6H8 in application.
How do the “absence of any therapeutically effective amount of a pharmaceutically active drug substance” limits interact with concomitant therapy?
Claims 5 and 9 allow concomitant treatment: the patient “also receives treatment concomitantly or in conjunction with one or more additional eye compositions comprising pharmaceutically active ingredients.”
This creates a common interpretive structure:
- Claims 1 and 6 require that the F6H8 administration itself is done in the absence of any therapeutically effective amount of a pharmaceutically active drug substance useful for topical ophthalmic treatment of KCS.
- Claims 5 and 9 permit that the patient may also use other active ophthalmic compositions at the same time period (or as additional compositions) but those other actives are not part of the F6H8 dose formulation satisfying the “absence” limitation, as drafted.
For litigation or design-around thinking, the key is whether an accused product is a fixed combination where the F6H8 formulation itself contains an ophthalmic KCS active at a therapeutically effective amount. Fixed combinations are more likely to collide with the “absence” language.
What patient and clinical phenotypes are covered by dependent claims? (dysfunctional ducts and lipid tear film deficiency)
Dependent claims 2 and 3 narrow within the KCS-MGD population:
- Claim 2: dysfunctional meibomian gland ducts.
- Claim 3: lipid tear film deficiency plus condition and symptoms of KCS (still tied to MGD).
These limitations may matter for evidentiary burden in enforcement. In practice, KCS-MGD patients often have overlapping signs, but the dependent claims may be asserted selectively to increase match precision.
How broad is coverage of anatomical application sites? (cornea/conjunctiva vs lids/eyelid anatomy)
Claims 1 and 6 require cornea or conjunctiva with spread.
Claim 8 extends to:
- upper/lower lid margins
- meibomian gland ducts
- eyelashes
- any area of eyelid anatomy
This dependent claim can enlarge practical infringement theories where an operator applies F6H8 by wiping the lid margins or applying to eyelid regions rather than only instilling on cornea/conjunctiva.
How does US 10,449,164 likely compare to other dry eye / meibomian gland dysfunction patent strategies?
Based on the claim set provided, US 10,449,164’s differentiator is the use of a specific semifluorinated alkane and a physical meibum solubilization/removal mechanism enforced through tight formulation and “absence of active drug” language. Typical dry eye/MGD landscapes often feature:
- anti-inflammatory actives (steroids, cyclosporine, lifitegrast, etc.)
- secretagogues
- lipid-containing lubricants
- antibiotics or anti-rosacea therapies
- thermal/mechanical disruption or gland expression devices
- surgical/occlusive approaches
In contrast, this estate claims a topical liquid semifluorinated alkane designed to spread and interact with meibum to clear obstructive material. The “absence of therapeutically effective amount” of KCS actives acts as a boundary against conventional pharmacologic dry eye therapies.
What is the likely enforcement focus for US 10,449,164? (method steps vs composition claims)
Your provided claims are method-of-treatment steps, not composition-product claims. That drives enforcement toward:
- how the product is administered
- what it consists of at the dosing site
- the patient’s condition alignment (KCS caused by MGD)
- whether it is used alone (no KCS active in the administered F6H8 dose)
If a competitor makes a meibum-solubilizing liquid using a different fluorinated alkane, it may avoid the F6H8 identity limitation. If it uses F6H8 but changes the formulation to include a KCS active drug, it may fail the “absence” limitation. If it uses F6H8 but with water/preservatives, it may avoid the “absence of water/preservative” dependent claims, while still risking exposure under claim 1 if asserted on the broader formulation-independent aspects.
Patent landscape: what other US patents might interact with 10,449,164?
No additional patents, citations, or assignee data were provided for US 10,449,164 beyond the claim text. Under the constraints here, a complete landscape mapping (family members, continuations, continuations-in-part, related use patents, prosecution history, or any Orange Book / listed FDA products) cannot be produced from the information in your prompt alone.
Key takeaways
- US 10,449,164 claims a specific topical method using F6H8 (F(CF2)6(CH2)8H(F6H8)) to solubilize meibum and remove obstructive meibum from obstructed meibomian gland ducts in KCS caused by MGD.
- The method requires cornea or conjunctiva topical administration with spreading over the ocular surface.
- Scope is constrained by absence limits:
- no water and no preservative in claims 4 and 6;
- no therapeutically effective amount of a pharmaceutically active KCS drug substance in the F6H8 administration in claims 1 and 6.
- Dependent claim 8 expands application to lid margins/eyelid anatomy.
- Dependent claims 10–11 are strict: the administered composition must consist of F6H8.
- Concomitant active eye therapies are permitted in dependent claims 5 and 9, but the “absence of therapeutically effective KCS active drug substance” appears to bind the F6H8 administration itself.
FAQs
1) Does US 10,449,164 require that F6H8 be applied directly to the cornea only?
No. Claims 1 and 6 require topical administration to the cornea or conjunctiva with spreading over that surface.
2) Can the patient receive standard dry eye or MGD medications alongside F6H8?
Claims 5 and 9 state that the patient can receive concomitant or additional eye compositions with pharmaceutically active ingredients, while claims 1/6 require the F6H8 administration itself to be in the absence of a therapeutically effective amount of a KCS-active drug substance.
3) What happens if the F6H8 product is aqueous or contains a preservative?
Claims 4 and 6 include “absence of water” and “absence of preservative,” so an aqueous/preserved formulation avoids those dependent limitations but may still face exposure under broader limitations in claim 1 as provided.
4) What is the effect of using a different semifluorinated alkane instead of F6H8?
The method claims are tied to the defined alkane identity: F(CF2)6(CH2)8H(F6H8) / F6H8. Using a different alkane risks avoiding the identity limitation.
5) Are the claims limited to any specific delivery device?
The provided claims are written around topical administration and anatomical locations, not a specific device. The critical elements are where and how the material spreads and whether it meets the formulation and absence restrictions.
